ATE359808T1 - Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma - Google Patents

Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Info

Publication number
ATE359808T1
ATE359808T1 AT01995681T AT01995681T ATE359808T1 AT E359808 T1 ATE359808 T1 AT E359808T1 AT 01995681 T AT01995681 T AT 01995681T AT 01995681 T AT01995681 T AT 01995681T AT E359808 T1 ATE359808 T1 AT E359808T1
Authority
AT
Austria
Prior art keywords
sarp
treat
scleroderma
prevent
prevent scleroderma
Prior art date
Application number
AT01995681T
Other languages
English (en)
Inventor
Christine Plater-Zyberk
Christine Power
Jacques Colinge
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE359808T1 publication Critical patent/ATE359808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT01995681T 2000-12-06 2001-11-30 Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma ATE359808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17

Publications (1)

Publication Number Publication Date
ATE359808T1 true ATE359808T1 (de) 2007-05-15

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995681T ATE359808T1 (de) 2000-12-06 2001-11-30 Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Country Status (29)

Country Link
US (2) US7341995B2 (de)
EP (2) EP1806144A3 (de)
JP (1) JP2004525869A (de)
KR (1) KR100804885B1 (de)
CN (1) CN1323716C (de)
AT (1) ATE359808T1 (de)
AU (2) AU2636602A (de)
BG (1) BG107941A (de)
BR (1) BR0115983A (de)
CA (1) CA2428092A1 (de)
CY (1) CY1107687T1 (de)
CZ (1) CZ20031855A3 (de)
DE (1) DE60128009T2 (de)
DK (1) DK1411970T3 (de)
EA (1) EA005973B1 (de)
EE (1) EE200300213A (de)
ES (1) ES2281463T3 (de)
HR (1) HRP20030426A2 (de)
HU (1) HUP0302738A3 (de)
IL (1) IL156069A0 (de)
MX (1) MXPA03005027A (de)
NO (1) NO20032597L (de)
NZ (1) NZ525774A (de)
PL (1) PL365316A1 (de)
PT (1) PT1411970E (de)
SK (1) SK8472003A3 (de)
UA (1) UA83790C2 (de)
WO (1) WO2002046225A2 (de)
YU (1) YU45103A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279575A1 (en) * 1997-02-06 1998-08-13 Genetics Institute, Inc. Human sdf-5 protein and compositions
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2003084560A2 (en) 2002-04-10 2003-10-16 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
BRPI0607639B1 (pt) * 2005-02-08 2022-04-05 Genzyme Corporation Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica
EP1948210A4 (de) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov Verfahren zur behandlung von ischämischer herzkrankheit
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
KR20140019364A (ko) * 2011-03-11 2014-02-14 셀진 코포레이션 면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2-6-디온의 용도
WO2022217037A1 (en) 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2266325C (en) * 1996-09-24 2012-07-17 Lxr Biotechnology, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
CA2279575A1 (en) * 1997-02-06 1998-08-13 Genetics Institute, Inc. Human sdf-5 protein and compositions
CN100480266C (zh) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途

Also Published As

Publication number Publication date
EP1411970B1 (de) 2007-04-18
NO20032597D0 (no) 2003-06-06
US20080107627A1 (en) 2008-05-08
DE60128009T2 (de) 2007-08-23
DE60128009D1 (de) 2007-05-31
IL156069A0 (en) 2003-12-23
EP1411970A2 (de) 2004-04-28
US7655628B2 (en) 2010-02-02
EP1806144A2 (de) 2007-07-11
EE200300213A (et) 2003-08-15
HUP0302738A3 (en) 2010-01-28
KR20030076585A (ko) 2003-09-26
CA2428092A1 (en) 2002-06-13
NZ525774A (en) 2006-03-31
WO2002046225A2 (en) 2002-06-13
ES2281463T3 (es) 2007-10-01
PL365316A1 (en) 2004-12-27
WO2002046225A3 (en) 2004-01-08
US7341995B2 (en) 2008-03-11
HK1068106A1 (zh) 2005-04-22
DK1411970T3 (da) 2007-06-04
EA005973B1 (ru) 2005-08-25
HRP20030426A2 (en) 2005-04-30
US20050113291A1 (en) 2005-05-26
MXPA03005027A (es) 2003-09-05
JP2004525869A (ja) 2004-08-26
KR100804885B1 (ko) 2008-02-20
HUP0302738A2 (hu) 2003-11-28
SK8472003A3 (en) 2003-10-07
AU2002226366B2 (en) 2007-03-22
UA83790C2 (ru) 2008-08-26
YU45103A (sh) 2006-08-17
BR0115983A (pt) 2003-12-30
BG107941A (bg) 2004-01-30
PT1411970E (pt) 2007-05-31
CZ20031855A3 (cs) 2003-09-17
NO20032597L (no) 2003-06-06
CN1553806A (zh) 2004-12-08
EP1806144A3 (de) 2008-04-23
CY1107687T1 (el) 2012-05-23
CN1323716C (zh) 2007-07-04
EA200300639A1 (ru) 2003-12-25
AU2636602A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
PL373528A1 (en) Medicine for preventing and treating bromidrosis
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE228840T1 (de) Neue verwendung von ropivacain zur schmerzbehandlung
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411970

Country of ref document: EP

EEFA Change of the company name